What are the odds of serious complications from donating bone marrow?
Evidence quality 4.88/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 5/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 5/5
- D4 Uncertainty
- 5/5
- D5 Scope
- 5/5
- D6 Prose
- 5/5
- D7 Perception honesty
- 4/5
- D8 Caveat completeness
- 5/5
Lifetime probability · lifetime, activity-specific
1 in 167
0.6% lifetime chance
Most people overestimate this.
range 1 in 333 to 1 in 42
● your factors — click this risk ▾ to reveal
≈ As likely as
Perceived
Bone marrow donation carries a disproportionate fear burden relative to its actual risk profile. The phrase "bone marrow" evokes images of long needles inserted into the hip, general anesthesia, and weeks of painful recovery — imagery that has persisted even as the majority of donations have shifted to peripheral blood stem cell (PBSC) collection, which involves no surgery at all. Surveys of potential registry joiners consistently identify fear of the procedure as the primary barrier to registration, ahead of time commitment or inconvenience. The perception is further inflated by dramatic anecdotes shared online and a general conflation of discomfort (which is common) with serious medical harm (which is rare).
Rough estimate: Many potential donors assume a significant risk of lasting harm or even death
Source: editorial intuition, not polled
Actual
~0.6% serious adverse events for PBSC donors; ~2.4% for marrow donors
unrelated NMDP donors, 2004-2009 cohort
Show derivation
Uses the PBSC serious adverse event rate of 0.56% from the Halter et al. 2009 NMDP prospective trial as the baseline, since PBSC now accounts for the majority of unrelated donor collections. The figure represents the per-donation risk, not a cumulative lifetime probability, because most donors donate only once. Life-threatening events occur at roughly 1 in 1,000 donations. No fatalities were documented in the NMDP cohort.
Caveats: The normalized figure uses the per-donation PBSC SAE rate because most unrelated…
The normalized figure uses the per-donation PBSC SAE rate because most unrelated donations now use PBSC. For traditional bone marrow harvest under general anesthesia, the SAE rate is roughly four times higher (2.4%). The WMDA has documented one donor death in over 250,000 collections worldwide — a rate below 1 in 200,000. Most side effects (bone pain, fatigue, headache from G-CSF) are transient and resolve within days of collection.
Risks at similar odds
Other risks with roughly the same likelihood — useful for calibration.
Childhood cancer diagnosis
What are the odds of a child being diagnosed with cancer before age 20?
Counterfeit medicine
What are the odds of being harmed or killed by a counterfeit or substandard medicine?
COVID-19
What are the odds of dying from COVID-19 over the course of the pandemic and endemic era?
Recently viewed on this device
Stored locally — clear anytime.
Pick challenger
The fear of donating bone marrow consistently outpaces the actual risk. In the largest prospective study of unrelated PBSC donors conducted by the NMDP, serious adverse events occurred in 0.6% of 2,408 donors, with life-threatening events at roughly 1 in 1,000. No fatalities were recorded. For traditional bone marrow harvest — which now accounts for the minority of unrelated donations — the serious adverse event rate is higher at around 2.4%, driven primarily by complications of general anesthesia and mechanical tissue injury at the collection site. The WMDA, which tracks outcomes globally, has documented a single donor death among more than 250,000 collections between 1988 and 2018.
The shift from surgical marrow harvest to PBSC collection via filgrastim mobilization has materially improved the safety profile. PBSC donors receive several days of G-CSF injections that cause bone pain, headache, and fatigue in a majority of cases — unpleasant but transient symptoms that resolve within a week. The serious-adverse-event rate for PBSC is roughly one-quarter that of marrow harvest. A theoretical long-term concern about filgrastim and subsequent cancer risk has not been borne out: the Halter et al. 2014 study found no increased cancer incidence in PBSC donors compared to the general population at median follow-up exceeding five years.
The practical barrier is perception, not biology. Registry drives routinely report that fear of the procedure is the top reason potential donors decline to register, ahead of logistics or time commitment. The mental model most people carry — a large needle into the hip bone under general anesthesia — describes one collection method that is increasingly uncommon. The actual experience for the majority of modern donors looks more like a blood donation with a few days of flu-like side effects beforehand. For context, the per-event serious complication rate of PBSC donation is comparable to that of a routine blood donation requiring medical follow-up.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] Bone Marrow Transplantation / Nature Publishing Group — Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program
Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program- Statistic
0.6% of 2,408 PBSC donors experienced serious adverse events; 6% experienced grade III-IV toxicities; no fatalities- Excerpt
“"Serious and unexpected toxicities occurred in 0.6% of donors. Grade III-IV adverse events occurred in 6% of donors. No fatalities were observed in this prospective cohort of 2,408 unrelated PBSC donors." ”
- Source data from
- 2009-04-01
- Accessed
- 2026-04-18 · archived copy
- Calculation
- The 0.6% serious adverse event rate among PBSC donors is the central estimate. This prospective NMDP trial tracked 2,408 unrelated donors from filgrastim mobilization through collection and 1-year follow-up. Grade III-IV events (6%) include expected side effects of G-CSF such as bone pain and headache that resolve after collection. The 0.6% figure captures events that were both serious and unexpected — the threshold relevant to the fear question.
-
[2] Blood / American Society of Hematology — Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation
Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation- Statistic
SAE rate 0.56% for PBSC vs 2.38% for BM; life-threatening events 0.31% PBSC vs 0.99% BM; no donor deaths in NMDP cohort- Excerpt
“"Bone marrow donors had a higher rate of serious adverse events at 2.38% compared to 0.56% for peripheral blood stem cell donors. Life-threatening, serious unexpected, or chronic/disabling events occurred in 0.99% of BM donors vs 0.31% of PBSC donors." ”
- Source data from
- 2014-06-05
- Accessed
- 2026-04-18 · archived copy
- Calculation
- This study compared SAE rates between BM and PBSC donation within the NMDP registry (donors 2004-2009). The threefold difference in life-threatening events (0.99% BM vs 0.31% PBSC) is clinically significant and explains the shift toward PBSC as the preferred collection method. No increased cancer risk was observed in long-term follow-up of PBSC donors, addressing a theoretical concern about filgrastim use.
-
[3] NMDP (formerly Be The Match) — Bone Marrow & Blood Stem Cell Donor FAQs
Bone Marrow & Blood Stem Cell Donor FAQs- Statistic
Fewer than 1% of PBSC donors experience serious side effects; no deaths reported in NMDP donor population- Excerpt
“"Fewer than 1% of donors experience serious side effects from PBSC donation. The National Marrow Donor Program has facilitated more than 100,000 transplants and closely monitors donor safety." ”
- Source data from
- 2025-01-01
- Accessed
- 2026-04-18 · archived copy
- Calculation
- NMDP's public-facing FAQ summarizes the peer-reviewed data in accessible terms. The "<1% serious" figure aligns with the 0.56% from the Halter et al. prospective trial. NMDP notes no donor deaths in its registry, consistent with WMDA data reporting only one death in over 250,000 collections worldwide between 1988 and 2018.